How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)

Your mitochondria are running two separate problems at the same time, and SS-31 and MOTS-c solve different ones.

The first problem is structural. The inner membrane of your mitochondria is lined with a molecule called cardiolipin, which acts like a scaffolding material that holds the electron transport chain in the right shape so it can produce energy efficiently. As you age, cardiolipin gets oxidized and damaged, and when the scaffolding warps, the proteins sitting on it warp too, and energy output drops. SS-31 is a peptide that concentrates specifically at that inner membrane and binds directly to cardiolipin, stabilizing it and reducing the oxidative damage that degrades it over time.

The second problem is functional. Even if your mitochondrial structure is intact, the cell needs a signal to keep running metabolic processes efficiently, to clear out damaged mitochondria, to maintain insulin sensitivity, and to regulate how much energy it burns. MOTS-c is something called a mitochondrial-derived peptide, which means it is a signaling molecule your own mitochondria produce naturally, encoded in the mitochondrial genome itself. When mitochondria are under stress, they release MOTS-c as a distress signal that triggers downstream gene expression changes, and those changes push the cell toward repair and metabolic efficiency.

Two problems, two tools. That is the whole map.

Now here is where dosing gets interesting, because each peptide has a completely different relationship between blood levels and effect.

SS-31 has a half-life of roughly two hours, which means it clears your bloodstream fast. But the effect is not tied to how long it circulates. The peptide concentrates approximately five thousand fold at the inner mitochondrial membrane, so even a small dose achieves a very high local concentration right where it needs to work, and the structural repair it enables accumulates over weeks of consistent exposure. The PROGRESS-HF trial compared 4 milligrams against 40 milligrams in heart failure patients and found no functional advantage at the higher dose, which tells you the lower end of the range is already saturating the mechanism. Daily dosing at 1 to 5 milligrams is the practical window, with 2 milligrams being a reasonable starting point for most people.

MOTS-c works differently. Its plasma half-life is also short, but the mechanism does not depend on sustained blood levels because it is not acting on a receptor in real time. It is triggering gene expression changes through something called the AMPK and PGC-1alpha pathway, which are the master regulators of mitochondrial biogenesis and metabolic adaptation. Once those genes are activated, the downstream effects keep running long after the peptide itself is gone. A 2021 study in Nature Communications found that after a loading phase, dropping to three times per week maintained all the benefits that daily dosing had produced. The signal does not need to be constant because the cellular changes it triggers are self-sustaining for days. The practical range is 5 to 15 milligrams per week, distributed across three injections.

If you are putting both together, the structure looks like SS-31 every day and MOTS-c on Monday, Wednesday, and Friday. A reasonable starting protocol is 2 milligrams of SS-31 daily and 10 milligrams of MOTS-c per week. New users should start at half those amounts to assess tolerance. People dealing with significant age-related metabolic or cardiovascular decline can push to 5 milligrams SS-31 daily and 15 milligrams MOTS-c weekly.

Now about cycling, because this is where most people are getting it wrong.

The standard advice in peptide communities is to run 8 to 12 weeks on, then 4 to 8 weeks off. That protocol makes sense for peptides that work through receptors, because receptors downregulate when they are chronically stimulated, and you need the off period to let sensitivity recover. SS-31 does not bind a receptor at all. It binds cardiolipin, which is a structural lipid, not a protein receptor with any capacity for desensitization. The Thompson et al. trial published in Genetics in Medicine ran SS-31 continuously for 168 weeks in Barth syndrome patients, a mitochondrial cardiomyopathy, and found progressive improvement over that entire period with no tolerance development.

MOTS-c has a different reason it should not need cycling. It is a peptide your own mitochondria produce endogenously, and there is no known feedback loop that suppresses natural production when you supplement it externally. This is meaningfully different from something like exogenous testosterone, where the body reads the external signal and shuts down its own production. In animal studies, MOTS-c was administered chronically for the lifespan of the subjects with sustained benefits and no reported attenuation of effect.

The cycling recommendation in this protocol is precautionary, not mechanistically justified. It exists because there is no long-term human data at these specific doses, and caution in the absence of data is reasonable. But you should understand that the cycle-off is not protecting you from a tolerance mechanism that has been demonstrated to exist. It is a hedge against things we have not yet measured.

One more thing to be direct about: no published human study has ever combined SS-31 and MOTS-c together. The combination protocol is built on the logic that their mechanisms are parallel and non-overlapping, SS-31 addressing structural membrane integrity and MOTS-c addressing metabolic signaling, so they should not interfere with each other and may compound benefits. The closest published evidence is a 2020 study in Aging Cell that combined SS-31 with NMN in aged mice and found synergistic improvements in cardiac metabolism, which supports the general principle that mitochondria-targeted interventions can stack without diminishing returns. But that is not the same as direct combination data for these two.

The evidence for each compound individually is real. The logic for combining them is sound. The human data for the combination does not yet exist. Those are three different things, and understanding which category each piece of information falls into is the difference between using these tools intelligently and just following a protocol someone handed you.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
2. Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
4. Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
5. Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
6. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness